20 years of Cure Parkinson's
We’re here for the cure! This year marks 20 years since Cure Parkinson’s was founded by four people living with Parkinson’s who felt that nobody was taking a cure seriously enough and that there was an urgent need for a focused approach to curative research...
Learn more
New biotech company focused on cell transplantation for Parkinson’s
Biotech company Ryne Bio has received a large research grant from CIRM to develop their late-stage preclinical cell transplantation procedure for Parkinson’s.
Sun Pharma shines on c-ABL
Sun Pharma have published data on their new drug vodobatinib which is a c-ABL inhibitor – c-ABL is over-active in the brains of people with Parkinson’s.
Cure3 2023 raises almost £700,000 in most successful edition to date
Cure Parkinson’s, in association with Bonhams and Artwise, is delighted to announce that the 2023 acclaimed selling art exhibition Cure3 has raised almost £700,000 making this the most successful edition of the project so far. All profits will go directly to support Cure Parkinson’s vital…
Payroll Giving Month 2023: how you can help your employees support the causes they care about
Cure Parkinson’s is pleased to announce that a large-scale phase 3 clinical trial of ambroxol, to determine whether the drug can slow the progression of Parkinson’s.
Cure Parkinson’s announces new chair of trustees
We are delighted to announce Peter Berners-Price as chair of our board of trustees.